A new survey of UK radiologists finds that 100% of NHS trusts have now used pre-biopsy MRI, although variations persist in ...

Prostate cancer is one of the most common cancers in men but often goes unnoticed. Experts stress early screening, awareness ...

Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of ...

Liv Hospital integrates PET/CT diagnostics, radionuclide therapies and a multidisciplinary council to create individualized treatment plans for complex cancer and cardiac cases.

There is a shadow disease that often lurks unnoticed, growing quietly within a man’s body which is hidden behind the mundane routine of daily life, masked by ag ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

A Guisborough man's friend who died from prostate cancer ultimately saved his life after prompting him to push for tests.

Prostate cancer is still associated with fear and social stigma, despite being the second most common cancer among men and one that needs attention. A urologist explained that advances in treatment ...

Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to ...

A published case series reports unexpected cancer remissions linked with fenbendazole use, prompting renewed discussion on ...

An update from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) is now available.

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private ...